Duloxetine Capsule, Delayed Release
Product Images NDC 67877-264

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 67877-264). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine-20mg-1000s (Duloxetine 20mg 1000s)

Label for Duloxetine delayed-release capsules USP 20 mg, manufactured by Alkem Laboratories Ltd and distributed by Ascend Laboratories, LLC. The label shows the quantity of 1,000 capsules, the NDC 67877-263-10, and storage instructions at 25°C (77°F) with allowed excursions. It includes directions to dispense a medication guide and warnings about moisture protection and inner seal integrity.*

FDA Label Image

Duloxetine-30mg-100s (Duloxetine 30mg 100s)

Label for Duloxetine delayed-release capsules USP 30 mg, supplied by Ascend Laboratories, LLC. The label indicates 100 capsules per container, with dosing information, storage instructions, and manufacturing by Alkem Laboratories Ltd., Mumbai, India. It includes a pharmacist advisory to dispense a medication guide with each patient and a caution not to use if the inner seal is missing or broken.*

FDA Label Image

Duloxetine-60mg-30s (Duloxetine 60mg 30s)

Label for Duloxetine delayed-release capsules USP 60 mg, manufactured by Alkem Laboratories Ltd. and distributed by Ascend Laboratories, LLC. The label indicates the capsules contain duloxetine hydrochloride equivalent to 60 mg duloxetine and comes in a package of 30 capsules. It includes storage instructions, a pharmacist dispensing note, and a barcode.*

FDA Label Image

Duloxetine Fig 5

A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline. The chart compares Duloxetine HCL 60 mg taken twice daily, Duloxetine HCL 60 mg taken once daily, and placebo groups, showing differences in pain improvement percentages across various improvement thresholds.*

FDA Label Image

Duloxetine Fig 6

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for different oral Duloxetine HCL dosages (120 mg, 60 mg, 20 mg once daily) and placebo. The graph shows a decline in patient improvement percentage with increasing pain improvement, with Duloxetine lines above placebo.*

FDA Label Image

Duloxetine-fig3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved with Duloxetine HCl 60 mg BD, 60 mg QD, 20 mg QD, and placebo over increasing percent improvement in pain from baseline. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. Duloxetine treatments show higher patient improvement percentages than placebo across the range.*

FDA Label Image

Duloxetine-fig4 (Duloxetine Fig4)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline for Duloxetine HCl 60mg taken twice daily (BD), Duloxetine HCl 60mg taken once daily (QD), and placebo. The graph shows the efficacy trends of these three groups across various levels of pain improvement.*

FDA Label Image

Duloxetine-fig7 (Duloxetine Fig7)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The y-axis shows the percentage of patients improved, and the x-axis indicates the percent improvement in pain from 0 to 100 percent.*

FDA Label Image

Duloxetine-fig8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved over different levels of percent improvement in pain from baseline, showing two groups: placebo and Duloxetine 60 mg once daily. The x-axis represents percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved.*

FDA Label Image

Duloxetine-figure1 (Duloxetine Figure1)

A Kaplan-Meier plot showing the proportion of patients with relapse over time from randomization (days) comparing placebo and duloxetine treatment groups. The graph displays time on the x-axis ranging up to 250 days, and proportion of patients with relapse on the y-axis from 0 to 1, with separate curves for placebo (higher relapse rate) and duloxetine (lower relapse rate).*

FDA Label Image

Duloxetine-figure2 (Duloxetine Figure2)

A line graph depicting the proportion of patients with relapse over time in days from randomization. The graph compares two treatments, placebo and duloxetine, showing a higher relapse proportion for placebo than duloxetine over approximately 275 days.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure of Duloxetine, showing the molecular arrangement including aromatic rings, a thiophene group, and an amine hydrochloride moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.